antibody

MPO, Mouse, mAb 8F4

MBS584425

0.1 mg

685 USD

monoclonal

mouse

nonconjugated

flow cytometry, FACS

Antibody

MPO, Mouse, mAb 8F4

MPO

myeloperoxidase; Myeloperoxidase; myeloperoxidase; myeloperoxidase

MPO

MPO; MPO; MPO

PERM_HUMAN

Monoclonal

IgG1

Mouse

Cross reactant: Rat MPO. Reactivity: Yes

745

1 ml (100 ug/ml) 0.2 um filtered antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide.

Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for one year.

F 3,4 , Flow Cytometry (FC 2,5 /FACS), Immunoassay (IA) 1,3

Application Use: For flow cytometry and immunohistology dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Immunogen: Purified mouse MPO from WEHI-3 cells

Negative Control: Lymphocytes isolated from digested infarcts. Positive Control: Neutrophils isolated from digested infarcts

Product Description: The monoclonal antibody 8F4 recognizes mouse myeloperoxidase (MPO). MPO is a glycoprotein produced as a single precursor, which is subsequently cleaved into a alpha and beta chain. In human the biologically active MPO is a 150kDa tetramer composed of 2 glycosylated alfa chains of 59-64 kDa and 2 beta chains of 14 kDa.- MPO is- stored in azurophilic granules of polymorphonuclear leukocytes and is rapidly released into the phagosome and extracellular space during inflammatory conditions.The enzyme catalyzes the conversion of chloride and hydrogen peroxide to hypochlorite, a potent oxidant, which functions in host defense against microorganisms. Involvement of MPO has been described in several human diseases, such as cardiovascular disease, airway inflammation, lung cancer, Alzheimer's disease and multiple sclerosis. A positive correlation between elevated MPO levels in serum and cardiovascular disease suggest an interesting role for MPO as an diagnostic marker, making it possible to identify patients at risk for future cardiac events. Furthermore, there are some autoimmune diseases, in which MPO is targeted by antineutrophil cytoplasm antibodies. Studies with MPO-knockout mice have shown an- increased susceptibility to pneumonia following intratracheal infections. Moreover, MPO deficient- mice are more susceptible to experimental autoimmune encephalitis, a T cell-dependent neuronal disease, and have an increased expression of arteriosclerotic plaques compared to wild-type mice. The anti-mouse MPO monoclonal antibody 8F4 recognizes natural MPO in biological solutions by ELISA,- in frozen tissue sections fixed with acetone and in flow cytometry using a- cell permeabilization method. The antibody 8F4 is cross-reactive- with rat MPO

1. Huugen, D et al; Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005, 167: 47 2. Wang, D et al; C/EBPalpha directs monocytic commitment of primary myeloid progenitors. Blood 2006, 108:1223. 3. Matthijsen, M et al; Myeloperoxidase is critically involved in the induction of organ damage after renal ischemia reperfusion. Am J Pathol 2007, 171: 1743. 4. Leeuwen van, M et al; Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR -/- mice. Arterioscler Thromb Vasc Biol 2008, 28: 84. 5. Nahrendorf, M et al; An activatable MR imaging agent reports myeloperoxidase activity in healing infarcts and detects the anti-inflammatory effects of atorvastatin on ischemia-reperfusion injury non-invasively. Circulation 2008, 117: 1153

4557759

NP_000241.1

NM_000250.1

87,248 Da

C-MYB Transcription Factor Network Pathway (138073); Folate Metabolism Pathway (198833); IL23-mediated Signaling Events Pathway (138000); Phagosome Pathway (153910); Phagosome Pathway (153859); Selenium Pathway (198825); Transcriptional Misregulation In Cancer Pathway (523016); Transcriptional Misregulation In Cancer Pathway (522987); Vitamin B12 Metabolism Pathway (920974); Amb2 Integrin Signaling Pathway (137945)

Myeloperoxidase (MPO) is a heme protein synthesized during myeloid differentiation that constitutes the major component of neutrophil azurophilic granules. Produced as a single chain precursor, myeloperoxidase is subsequently cleaved into a light and heavy chain. The mature myeloperoxidase is a tetramer composed of 2 light chains and 2 heavy chains. This enzyme produces hypohalous acids central to the microbicidal activity of netrophils. [provided by RefSeq, Jul 2008]

MPO: Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity. Homodimer; disulfide-linked. Each monomer consists of a light and a heavy chain. Belongs to the peroxidase family. XPO subfamily. 3 isoforms of the human protein are produced by alternative splicing. Protein type: EC 1.11.2.2; Oxidoreductase. Chromosomal Location of Human Ortholog: 17q23.1. Cellular Component: extracellular space; azurophil granule; mitochondrion; lysosome; nucleus; secretory granule. Molecular Function: heparin binding; peroxidase activity; metal ion binding; heme binding; chromatin binding. Biological Process: respiratory burst during defense response; response to food; removal of superoxide radicals; hydrogen peroxide catabolic process; response to mechanical stimulus; response to lipopolysaccharide; defense response; response to yeast; response to oxidative stress; defense response to fungus; negative regulation of apoptosis; aging. Disease: Myeloperoxidase Deficiency; Alzheimer Disease

0.1 mg

685 USD